Booth #1526
Flatiron is excited to attend and present our research at the 2024 San Antonio Breast Cancer Symposium, showcasing how our evidence solutions can be leveraged to bolster breast cancer research across the therapeutic development lifecycle.
We’re constantly pushing the realm of possibilities with evidence solutions that support oncology portfolios across the development lifecycle.
At SABCS, we’re excited to showcase new innovative solutions to bolster breast cancer research, including:
Panoramic data with maximum cohort sizes spanning disease settings from our network of over 750k breast cancer patients
>7k breast cancer patients linked across Flatiron’s best-in-class longitudinal clinical data and Caris’ industry-leading molecular data
Local real-world data (RWD) cohorts in the US, UK, Germany, and Japan
Prospective evidence generation stemming from pragmatically-designed clinical studies
Wednesday, December 11
3:30-4:00 CST
Exhibit Hall - Product Theatre B
Flatiron's evidence offerings have evolved to support the entire therapeutic development lifecycle from discovery to commercialization. In this session, Catherine Keane, RN, NP will share three customer case studies that demonstrate how biopharma is taking a holistic approach to breast cancer research, including:
Catherine Keane, RN, NP
Senior Clinical Director, Flatiron Health
Flatiron now offers access to data on all breast cancer patients in our network across the US, UK, Germany, and Japan.
We help sponsors generate prospective evidence through the pragmatic design and execution of low-interventional or observational studies enabled by our prospective study platform.
Our Clinical-Molecular Database (CMDB) offers Caris Life Sciences’ comprehensive whole-exome sequencing, whole-transcriptome sequencing and digital pathology data linked with Flatiron clinical data on over 56k+ linked patients.
Read more about how three life sciences companies leveraged Flatiron’s network of over 750k breast cancer patients to support crucial research at various stages of the drug development lifecycle.
Read moreRead more about our accepted research at this year’s conference.
Author affiliations: Flatiron Health, Pfizer, University of San Francisco Helen Diller Family Comprehensive Cancer Center, MD Anderson Cancer Center, Dana-Farber Cancer Institute, European Institute of Oncology IRCCS and University of Milano, UPMC Hillman Cancer Center
Using the Flatiron Health EHR-derived Panoramic database comprised of >650K patients with breast cancer, this study is the largest real-world comparative overall survival analysis of first-line CDK4/6 inhibitors plus aromatase inhibitor therapy in the treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer utilizing our expanded offering enabling a scaled, comprehensive review of data.
Date: Wednesday, December 11
Time: 7 - 8:30 AM CST
Presentation ID: P2-01-05
Aaron Cohen
Head of Research Oncology, Clinical Data
Connect on LinkedIn
Author affiliations: FFlatiron Health, Texas Oncology, Eli Lilly and Company, Moffitt Cancer Center and Research Institute
This retrospective study described clinical characteristics and treatment persistence in an older, less fit, and more racially diverse population of patients with HR+/HER2- node positive early breast cancer initiating abemaciclib than presented in the monarchE trial that initially established the efficacy of abemaciclib plus endocrine therapy for early breast cancer.
Date: Wednesday, December 11
Time: 12:30 - 2 PM CST
Presentation ID: P1-11-29
Maddy Franco
Senior Research Scientist
Connect on LinkedIn
Author affiliations: Flatiron Health, Dana-Farber Cancer Institute, University of Kansas Medical Center, University of North Carolina at Chapel Hill, University of Illinois Cancer Center, Analysis Group, Inc, Novartis, Wilmot Cancer Institute
This retrospective cohort study reaffirmed observed tolerability and safety reported across the MONALEESA randomized control trials that initially approved ribociclib plus endocrine therapy as a first-line treatment option for HR+/HER2- metastatic breast cancer.
Date: Thursday, December 12
Time: 12:30 - 2 PM CST
Presentation ID: P3-10-14
Taavy Miller
Senior Research Scientist
Connect on LinkedIn
Author affiliations: Flatiron Health, AstraZeneca, The Ohio State University Comprehensive Cancer Center
This retrospective cohort study found that 55% of patients with HR+/HER2- early breast cancer and 27% of patients with triple negative breast cancer did not receive a gBRAC test and saw low utilization of adjuvant olaparib, highlighting a gap in genetic testing and utilization of olaparib to treat eligible patients.
Date: Friday, December 13
Time: 12:30 - 2 PM CST
Presentation ID: PS2-03
Xinran Ma
Senior Research Scientist
Connect on LinkedIn
Leverage Flatiron’s industry-leading oncology solutions to unlock global insights in breast cancer research, including:
Panoramic data with maximum cohort sizes spanning disease settings from our network of over 750k breast cancer patients
>7k breast cancer patients linked across Flatiron’s best-in-class longitudinal clinical data and Caris’ industry leading molecular data
Local real-world data (RWD) cohorts in the US, UK, Germany, and Japan
Contact us to learn more about Flatiron’s flexible oncology evidence solutions.
